Market Overview

Tech futures are under pressure this morning as Samsung’s disappointing earnings triggered a broad selloff in the AI chip/memory complex, dragging Micron (-26% last week) and SanDisk lower. However, the S&P 500 and Dow are showing resilience near record highs, with Fundstrat’s Tom Lee calling for 8,000-8,800 by year-end after a potential 10-20% pullback. The market is bifurcated: defensive names and non-semiconductor growth stocks are catching bids while the chip trade rotates out.

Claude’s Call

FLAT — The chip selloff creates headline anxiety but the damage is concentrated in memory/semis; the broader S&P 500 likely treads water today as investors rotate into software, cybersecurity, and non-chip AI beneficiaries, with the Dow’s record-high momentum providing a floor.

Top Movers

RXT (+7.0%) — $6.84 → $8.50 (+24.3% upside) Thesis: Rackspace is riding the AMD partnership catalyst — the 30MW AI infrastructure deployment agreement signed in June is a genuine business inflection for a company trading near distressed levels. At RSI 35, this is a recovery trade with real fundamental backing, not just sympathy. The risk is that RXT has been a serial disappointer, so the move needs follow-through volume to confirm. Levels: Exit at $8.50 (prior resistance zone from Q1 2026). Support at $6.20 (recent swing low).

TEO (+5.4%) — $13.46 → $16.00 (+18.9% upside) Thesis: Telecom Argentina continues to benefit from Argentina’s economic reform narrative and screens as a Zacks “Fast-Paced Momentum at a Bargain” pick with an RSI of just 3.69 — absurdly oversold on a weekly basis despite strong daily gains, suggesting a violent mean reversion is underway. This is a macro bet on Argentina’s reform story holding together. Levels: Exit at $16.00 (prior consolidation zone). Support at $12.50 (week’s opening level).

AXON (+4.0%) — $647.52 → $750.00 (+15.8% upside) Thesis: Axon is the real deal today — Needham hiked its target to $750, LAPD doubled its annual spend to $22M, and the stock just crossed its 200-day SMA with World Cup drone defense contracts providing a secular tailwind. This is a high-quality compounder catching a bid on multiple catalysts simultaneously. The +27% weekly gain raises the question of chasing, but the 200-day crossover with RSI at 38 means it’s coming from deeply oversold territory. Levels: Exit at $750 (new analyst target, likely fib extension). Support at $600 (200-day SMA area).

VRNS (+3.0%) — $46.18 → $54.00 (+16.9% upside) Thesis: Cybersecurity sector-wide analyst upgrades are driving the move, and Varonis benefits from the chip-to-software rotation happening today. RSI at 36 with a +15% weekly gain from oversold levels suggests early innings of a recovery trade. The private equity buyout chatter mentioned in recent coverage provides a floor. Levels: Exit at $54.00 (pre-selloff consolidation). Support at $43.00 (recent week’s low).

RDDT (+2.4%) — $204.85 → $240.00 (+17.2% upside) Thesis: Reddit’s AI-powered spam detection announcement is a clever way to remind the market of its data licensing moat — if AI companies need Reddit’s data to train models, and Reddit is actively cleaning that data, it strengthens its negotiating position. The +17.5% weekly gain shows institutional accumulation. This is a genuine AI-data play, not just meme stock energy. Levels: Exit at $240 (prior resistance from earlier in 2026). Support at $185 (breakout level).

DUOL (+2.2%) — $132.72 → $160.00 (+20.6% upside) Thesis: Duolingo at RSI 13 with a “70% drop over the past year is extremely overdone” narrative gaining traction — DA Davidson’s DAU tracking data shows 21.7% growth vs. 20.4% consensus, beating guidance. This is a high-quality growth name that got punished with the broader growth selloff and is now bouncing from extreme oversold conditions. The deceleration in week-over-week DAU is the bear case, but at these levels the bar is low. Levels: Exit at $160 (50-day SMA area and prior support-turned-resistance). Support at $120 (recent swing low).

KLRA (+2.2%) — $23.80 → $28.00 (+17.6% upside) Thesis: Kailera just dropped Phase 3 data showing up to 11% weight loss from an oral small molecule — this is the GLP-1 oral play investors have been hunting for. The obesity/metabolic space rewards clinical milestones with explosive moves, and this data is fresh as of today. Pfizer M&A speculation adds a takeout premium. Levels: Exit at $28.00 (pre-selloff resistance). Support at $21.50 (week’s opening range).

Headlines to Watch

  • Samsung earnings miss triggers chip sector selloff — Memory and AI chip names (MU, SNDK, WDC) are the epicenter; if you own semis, this is a headwind for days, not hours.
  • Microsoft cutting 4,800 jobs while spending $190B on AI capex — The “cut workers, feed the AI machine” trade is now explicit; bullish for Azure/AI infrastructure, concerning for employee-heavy tech.
  • Fundstrat’s Tom Lee: S&P to 8,000-8,800 but 10-20% drop may come first — The most-followed strategist is bullish but warning of a correction; sets up buy-the-dip mentality on any pullback.
  • Micron insiders selling at highest rate since 2010 — When insiders dump their own stock at the best-performing SPX name, pay attention; this is a classic late-cycle warning sign for the memory trade.
  • Kailera Phase 3 oral weight loss data: 11% weight loss — Obesity drug competition is intensifying; oral GLP-1 alternatives are the next frontier and this readout validates the approach.
  • Axon expands LAPD deal, gets Needham $750 target — Law enforcement AI/drone spending is a bipartisan secular trend; Axon is the dominant platform with recurring revenue.
  • Reddit detects 25,000 daily spam posts targeting AI models — Quietly the most important AI-data-quality story; Reddit’s moat is the authenticity of its data for LLM training.

Claude’s Top Picks

AXON (+4.0% today, +26.8% week) — $647.52 → $750.00 (+15.8% upside) Valuation: At ~60x forward earnings on 30%+ revenue growth, the PEG is around 2x — expensive but justified by monopoly position in law enforcement tech with 95%+ retention rates. Upside: Triple catalyst stack (analyst upgrade, LAPD expansion, World Cup drone defense) with 200-day SMA crossover confirmation from deeply oversold levels. Risk: +27% in a week means any broad market pullback could trigger profit-taking; the stock is volatile and premium-valued.

DUOL (+2.2% today, +14.4% week) — $132.72 → $160.00 (+20.6% upside) Valuation: Trading at roughly 6x forward revenue after a 70% drawdown, down from 15x+ a year ago — cheap relative to its own history and peers like Zeta Global. Upside: RSI 13 is extreme oversold territory; DAU growth beating guidance provides fundamental support for a mean reversion to $150-160. Risk: Week-over-week DAU deceleration for three straight weeks could signal the growth engine is sputtering, not just normalizing.

KLRA (+2.2% today, +9.8% week) — $23.80 → $28.00 (+17.6% upside) Valuation: Pre-revenue clinical biotech, so EV/Revenue is irrelevant — value is in the pipeline; peer oral GLP-1 companies with Phase 3 data trade at $3-5B market caps. Upside: Fresh Phase 3 data today (11% weight loss) is a hard catalyst; Pfizer actively looking for obesity M&A targets per CEO comments. Risk: Biotech binary risk — any safety signal or regulatory setback could erase gains overnight; position size accordingly.

RDDT (+2.4% today, +17.5% week) — $204.85 → $240.00 (+17.2% upside) Valuation: At ~12x forward revenue for a 40%+ revenue grower with expanding margins, Reddit is at the cheaper end of its post-IPO range. Upside: AI data licensing narrative is strengthening with each product announcement; institutional accumulation is evident in the weekly gain pattern. Risk: Advertising revenue sensitivity to macro slowdown; if AI companies decide they don’t need Reddit data (or scrape it anyway), the licensing thesis collapses.

TEO (+5.4% today, +4.5% week) — $13.46 → $16.00 (+18.9% upside) Valuation: Single-digit P/E with strong momentum — screens as a Zacks Strong Buy with value characteristics; cheap relative to EM telecom peers. Upside: RSI of 3.69 on weekly timeframe is almost mathematically impossible to sustain; Argentine reform narrative provides macro tailwind. Risk: Argentina political risk is binary — any policy reversal or currency shock could crater the ADR regardless of fundamentals.

Avoid

ALHC (+3.3%) — RSI at 77 is the only stock on this list in overbought territory. Medicare Advantage tailwinds are real but the stock has already re-rated after earnings; chasing into overbought conditions after a +10.7% post-earnings gap is a poor risk/reward entry.

CNMD (+2.4%) — BofA just downgraded to Underperform and analysts lowered fair value from $48 to $40. The stock is bouncing on light volume with no clear catalyst; this is a value trap disguised as a bounce. Don’t catch this knife.

ALMS (+3.9%) — Despite bullish analyst coverage, revenue dropped from $17.4M to $1.7M year-over-year in Q1. A biotech burning $93M/quarter with no revenue to speak of needs pipeline catalysts to justify the price, and the next major readouts aren’t imminent. The move today looks like low-float noise.

WSB Sentiment Check

MU — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — Insiders are selling at the highest rate since 2010, Samsung just missed on earnings dragging the memory sector, and the stock dropped 26% last week. WSB is buying the dip into a falling knife with insider selling screaming “get out.” The bullishness is contrarian hopium, not conviction. Wait for stabilization.

MSFT — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — The 4,800 job cuts while spending $190B on AI capex is genuinely bullish for margins long-term, and MSFT at these levels is reasonably valued for a 15%+ grower. But the near-term setup is messy with layoff headlines creating sentiment drag. Agree on direction, disagree on timing.

NVDA — WSB says: BULLISH (80% bullish) Claude says: AGREE — NVDA remains the AI infrastructure pick-and-shovel play with best-in-class margins. The Samsung selloff creates splash damage but NVDA’s competitive moat is widening, not narrowing. Pullbacks are buying opportunities until datacenter capex rolls over.

SNDK — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — Down 26% in a single week as the worst Nasdaq performer, with Samsung earnings confirming memory sector weakness. WSB is averaging down into a sector in active de-rating. The memory cycle may have peaked; wait for the knife to hit the floor before catching it.

TSLA — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — Tesla’s robotaxi narrative and energy business provide optionality, but the auto fundamentals face pricing pressure. WSB is perpetually bullish on TSLA regardless of setup. The stock is a momentum name — trade it directionally but don’t pretend the valuation is justified by current earnings.